← Back

Wire · opportunities

Early test results for U.S. drug 'biggest breakthrough' for pancreatic cancer, says Canadian oncologist

Published

22 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Canada

◆ Source

Read at cp24.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Erasca's experimental drug ERAS-0015 showed significant tumour reduction in early trials for advanced pancreatic and lung cancers, with plans for late-stage trials in 2027 including Canadian participation. This follows another breakthrough drug, daraxonrasib, which doubled survival times for pancreatic cancer patients and is now licensed in the U.S.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to position your biotech firm to engage with clinical trials as pancreatic cancer treatments advance rapidly. The window opens now to align with US and Canadian trials and reshape cancer care offerings.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Biotechpancreatic-cancerclinical-trialsoncologybiotechdrug-development